PharmaBoardroom’s Top 5 Op-Eds in 2021 (So Far)
As our thoughts here at PharmaBoardroom turn towards the summer holidays, we are happy to share the five most-read articles from our global…
Tagged with Japan
Enhancing Patient Engagement in Clinical Trials in Japan
Writing in the July issue of DIA’s Global Forum magazine Pfizer R&D Japan’s Atsushi Kitamura examines how both pharmaceutical companies and…
Japan Oncology Market Snapshot 2021
While the overall Japanese pharma market is expected to remain at a similar overall value up to 2023, the oncology segment is expected to grow by five…
Impact of COVID-19 on US Clinical Studies Conducted by…
Writing in the June edition of DIA’s Global Forum magazine, representatives of Japanese pharmaceutical companies with US operations outline how the…
Takeda Pivoting to Growth Amid Renewed Focus on “Core Assets”
“This marks a significant moment in Takeda’s history and is an exciting step forward as we accelerate our transformation journey,” said…
Life Science VC Funding in Japan: Signs of Growth & Untapped…
Toshio Fujimoto, MD, MBA, the General Manager of Shonan Health Innovation Park examines why Japan – despite being well established as one of the…
Japan Pharma News: Takeda’s Revenue up 5x; First Domestic…
The latest from Japanese pharma, including Takeda’s big profit jump, British Linepharma’s quest to get the first ever induced abortion pill for…
Biosimilars & Biologics: Japan
The key facts about biosimilars and biologics in Japan. Prepared in association with Nishimura & Asahi, a leading law firm in Japan, this is an…
Localization: Japan
The key facts about localization in Japan. Prepared in association with Nishimura & Asahi, a leading law firm in Japan, this is an extract…
Japan PMDA New Drug Approvals 2020
Following on from our recent compilations of 2020 new drug approvals in the USA, China, and Switzerland, see below for the Japanese PMDA's new drug…
Japan’s Taiho Pharmaceutical: An Oral Chemotherapy Pioneer
Japanese pharma companies are already far lower-profile than their occidental counterparts but an even lesser-known player may be Taiho…
Eisai Targeting Global Leadership in Neurology & Oncology…
Founded by Toyoji Naito in December 1941, in just under 80 years, Eisai has become a leading global biopharma player, with pharmaceutical revenues of…
